metformin has been researched along with Hepatitis C, Chronic in 20 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Hepatitis C, Chronic: INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Insulin resistance (IR) affects sustained virological response (SVR) to peginterferon alfa plus ribavirin (PR) in patients with chronic hepatitis C (CHC)." | 9.19 | A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin. ( Chen, DS; Hsu, CS; Hsu, SJ; Kao, JH; Lin, HH; Tseng, TC; Wang, CC, 2014) |
| "A combination of metformin, peginterferon alfa-2a, and ribavirin improved insulin sensitivity and increased the SVR rate of patients with hepatitis C genotype 1 and IR, with a good safety profile." | 9.16 | The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance. ( Kang, P; Sun, LJ; Yan, BZ; Yu, JW; Zhao, YH, 2012) |
| "Adding metformin to peginterferon and ribavirin was safe and improved insulin sensitivity." | 9.14 | Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. ( Andrade, RJ; Calleja, JL; De la Mata, M; Diago, M; Durán, S; Fernández-Rodríguez, CM; García-Samaniego, J; Herrerías, JM; Moreno-Otero, R; Nuñez, O; Olveira, A; Planas, R; Romero-Gómez, M; Salmerón, J; Solà, R, 2009) |
| "To evaluate the safety and efficacy of metformin in patients with type 2 diabetes mellitus (T2DM) and chronic hepatitis C virus (HCV) with or without cirrhosis and hepatocellular carcinoma (HCC)." | 8.89 | Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. ( Harris, K; Smith, L, 2013) |
| "The current study provides evidence that metformin could reduce hepatocellular carcinoma (HCC) incidence after successful antiviral therapy among those with diabetes and chronic hepatitis C in a large-scale nationwide cohort study." | 8.31 | Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. ( Bair, MJ; Chen, CJ; Chen, CY; Chen, JJ; Cheng, JS; Cheng, PN; Chien, RN; Chiu, YC; Chu, CH; Chung, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Kuo, HT; Lai, HC; Lee, PL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Lo, GH; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Tung, SY; Wang, CC; Wang, JH; Yan, SL; Yang, CC; Yeh, ML; Yu, ML, 2023) |
| "To compare metformin and pioglitazone with standard interferon and ribavirin in achieving sustained virological response in chronic hepatitis C patients." | 7.85 | Comparison of metformin and pioglitazone in achieving sustained virological response in chronic hepatitis C patients with insulin resistance: A quasi-experimental study. ( Butt, NF; Hamid, S; Khan, IM; Malik, BR; Malik, U; Randhawa, FA, 2017) |
| "Insulin resistance (IR) affects sustained virological response (SVR) to peginterferon alfa plus ribavirin (PR) in patients with chronic hepatitis C (CHC)." | 5.19 | A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin. ( Chen, DS; Hsu, CS; Hsu, SJ; Kao, JH; Lin, HH; Tseng, TC; Wang, CC, 2014) |
| "A combination of metformin, peginterferon alfa-2a, and ribavirin improved insulin sensitivity and increased the SVR rate of patients with hepatitis C genotype 1 and IR, with a good safety profile." | 5.16 | The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance. ( Kang, P; Sun, LJ; Yan, BZ; Yu, JW; Zhao, YH, 2012) |
| "Adding metformin to peginterferon and ribavirin was safe and improved insulin sensitivity." | 5.14 | Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. ( Andrade, RJ; Calleja, JL; De la Mata, M; Diago, M; Durán, S; Fernández-Rodríguez, CM; García-Samaniego, J; Herrerías, JM; Moreno-Otero, R; Nuñez, O; Olveira, A; Planas, R; Romero-Gómez, M; Salmerón, J; Solà, R, 2009) |
| "To evaluate the safety and efficacy of metformin in patients with type 2 diabetes mellitus (T2DM) and chronic hepatitis C virus (HCV) with or without cirrhosis and hepatocellular carcinoma (HCC)." | 4.89 | Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. ( Harris, K; Smith, L, 2013) |
| "The current study provides evidence that metformin could reduce hepatocellular carcinoma (HCC) incidence after successful antiviral therapy among those with diabetes and chronic hepatitis C in a large-scale nationwide cohort study." | 4.31 | Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. ( Bair, MJ; Chen, CJ; Chen, CY; Chen, JJ; Cheng, JS; Cheng, PN; Chien, RN; Chiu, YC; Chu, CH; Chung, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Kuo, HT; Lai, HC; Lee, PL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Lo, GH; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Tung, SY; Wang, CC; Wang, JH; Yan, SL; Yang, CC; Yeh, ML; Yu, ML, 2023) |
| "Hepatitis C virus (HCV) infection has been related to increased risk of development of hepatocellular carcinoma (HCC) while metformin (M) and statins treatment seemed to protect against HCC development." | 3.88 | Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy. ( Ampuero, J; Del Campo, JA; Gallego, P; Gallego-Durán, R; García-Valdecasas, M; Gil-Gómez, A; Grande, L; Muntané, J; Padillo, FJ; Pastor, H; Rojas, Á; Romero-Gómez, M, 2018) |
| "To compare metformin and pioglitazone with standard interferon and ribavirin in achieving sustained virological response in chronic hepatitis C patients." | 3.85 | Comparison of metformin and pioglitazone in achieving sustained virological response in chronic hepatitis C patients with insulin resistance: A quasi-experimental study. ( Butt, NF; Hamid, S; Khan, IM; Malik, BR; Malik, U; Randhawa, FA, 2017) |
| "Insulin resistance is a risk factor for non-response to interferon/ribavirin therapy in patients with chronic hepatitis C." | 3.78 | Protein-tyrosine phosphatases are involved in interferon resistance associated with insulin resistance in HepG2 cells and obese mice. ( García-Ruiz, I; Gómez-Izquierdo, E; Muñoz-Yagüe, MT; Solís-Herruzo, JA; Solís-Muñoz, P; Valverde, AM, 2012) |
| "A total of 100 consecutive diabetic patients (53 men, age 61 ± 11 yr) with ongoing HCV cirrhosis and no contraindication for metformin were included in a screening program for hepatocellular carcinoma (HCC)." | 3.77 | Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. ( Aout, M; Beaugrand, M; Bourcier, V; Charif, I; Cosson, E; Ganne-Carrie, N; Grando-Lemaire, V; Mahmoudi, A; Nkontchou, G; Trinchet, JC; Vicaut, E, 2011) |
| " Pharmacokinetic curves were recorded at steady-state." | 2.84 | Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers. ( Aarnoutse, RE; Burger, DM; Colbers, A; de Kanter, CTMM; Drenth, JPH; Smolders, EJ; Tack, CJ; van Ewijk-Beneken Kolmer, N; Velthoven-Graafland, K; Wolberink, LT, 2017) |
| "Insulin resistance is a new target in the challenging management of chronic hepatitis C." | 2.46 | Insulin resistance and response to antiviral therapy in chronic hepatitis C: mechanisms and management. ( del Campo, JA; López, RA; Romero-Gómez, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (20.00) | 29.6817 |
| 2010's | 14 (70.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsai, PC | 1 |
| Kuo, HT | 1 |
| Hung, CH | 1 |
| Tseng, KC | 1 |
| Lai, HC | 1 |
| Peng, CY | 1 |
| Wang, JH | 1 |
| Chen, JJ | 1 |
| Lee, PL | 1 |
| Chien, RN | 1 |
| Yang, CC | 1 |
| Lo, GH | 1 |
| Kao, JH | 3 |
| Liu, CJ | 1 |
| Liu, CH | 1 |
| Yan, SL | 1 |
| Bair, MJ | 1 |
| Lin, CY | 1 |
| Su, WW | 1 |
| Chu, CH | 1 |
| Chen, CJ | 1 |
| Tung, SY | 1 |
| Tai, CM | 1 |
| Lin, CW | 1 |
| Lo, CC | 1 |
| Cheng, PN | 1 |
| Chiu, YC | 1 |
| Wang, CC | 3 |
| Cheng, JS | 1 |
| Tsai, WL | 1 |
| Lin, HC | 1 |
| Huang, YH | 1 |
| Yeh, ML | 1 |
| Huang, CF | 1 |
| Hsieh, MH | 1 |
| Huang, JF | 1 |
| Dai, CY | 1 |
| Chung, WL | 1 |
| Chen, CY | 1 |
| Yu, ML | 1 |
| Lin, D | 1 |
| Reddy, V | 1 |
| Osman, H | 1 |
| Lopez, A | 1 |
| Koksal, AR | 1 |
| Rhadhi, SM | 1 |
| Dash, S | 1 |
| Aydin, Y | 1 |
| Smolders, EJ | 1 |
| Colbers, A | 1 |
| de Kanter, CTMM | 1 |
| Velthoven-Graafland, K | 1 |
| Wolberink, LT | 1 |
| van Ewijk-Beneken Kolmer, N | 1 |
| Drenth, JPH | 1 |
| Aarnoutse, RE | 1 |
| Tack, CJ | 1 |
| Burger, DM | 1 |
| Khan, IM | 1 |
| Malik, BR | 1 |
| Randhawa, FA | 1 |
| Butt, NF | 1 |
| Malik, U | 1 |
| Hamid, S | 1 |
| Del Campo, JA | 2 |
| García-Valdecasas, M | 1 |
| Gil-Gómez, A | 1 |
| Rojas, Á | 1 |
| Gallego, P | 1 |
| Ampuero, J | 1 |
| Gallego-Durán, R | 1 |
| Pastor, H | 1 |
| Grande, L | 1 |
| Padillo, FJ | 1 |
| Muntané, J | 1 |
| Romero-Gómez, M | 3 |
| Harris, K | 1 |
| Smith, L | 1 |
| Hsu, CS | 1 |
| Hsu, SJ | 1 |
| Lin, HH | 1 |
| Tseng, TC | 1 |
| Chen, DS | 1 |
| Donadon, V | 1 |
| Balbi, M | 1 |
| Zanette, G | 1 |
| Diago, M | 1 |
| Andrade, RJ | 1 |
| Calleja, JL | 1 |
| Salmerón, J | 1 |
| Fernández-Rodríguez, CM | 1 |
| Solà, R | 1 |
| García-Samaniego, J | 1 |
| Herrerías, JM | 1 |
| De la Mata, M | 1 |
| Moreno-Otero, R | 1 |
| Nuñez, O | 1 |
| Olveira, A | 1 |
| Durán, S | 1 |
| Planas, R | 1 |
| Geroldi, D | 1 |
| Emanuele, E | 1 |
| Yilmaz, Y | 1 |
| Yonal, O | 1 |
| Imeryuz, N | 1 |
| López, RA | 1 |
| Rao, GA | 1 |
| Pandya, PK | 1 |
| Nkontchou, G | 1 |
| Cosson, E | 1 |
| Aout, M | 1 |
| Mahmoudi, A | 1 |
| Bourcier, V | 1 |
| Charif, I | 1 |
| Ganne-Carrie, N | 1 |
| Grando-Lemaire, V | 1 |
| Vicaut, E | 1 |
| Trinchet, JC | 1 |
| Beaugrand, M | 1 |
| Popov, VB | 1 |
| Lim, JK | 1 |
| Hokari, A | 1 |
| Yu, JW | 1 |
| Sun, LJ | 1 |
| Zhao, YH | 1 |
| Kang, P | 1 |
| Yan, BZ | 1 |
| García-Ruiz, I | 1 |
| Solís-Muñoz, P | 1 |
| Gómez-Izquierdo, E | 1 |
| Muñoz-Yagüe, MT | 1 |
| Valverde, AM | 1 |
| Solís-Herruzo, JA | 1 |
| Robertson, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Drug-drug Interaction Study Between the Novel Anti-hepatitis c Virus (HCV) Agent Daclatasvir and The Antidiabetic Agent Metformin in Healthy Volunteers[NCT02565862] | Phase 1 | 20 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Metformin as Adjunctive Therapy in Overweight and Obese Patients With Dengue: an Open-label Safety and Tolerability Trial[NCT04377451] | Phase 1/Phase 2 | 120 participants (Actual) | Interventional | 2020-07-27 | Completed | ||
| PRIMARY PREVENTION OF HEPATOCELLULAR CARCINOMA BY METFORMIN IN PATIENTS WITH VIRAL C CIRRHOSIS : PROSPECTIVE MULTICENTER STUDY, RANDOMIZED CONTROL TRIAL. Ancillary Study of the ANRS CO12 CirVir Cohort[NCT02319200] | Phase 3 | 11 participants (Actual) | Interventional | 2015-06-30 | Terminated (stopped due to Decision of investigator) | ||
| Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (ECF/TAF) Switch Followed by Ledipasvir-Sofosbuvir HCV Therapy in HIV-HCV Co-Infection: A CIHR Canadian HIV Trials Network-Gilead Pilot Trial Proposal[NCT02660905] | Phase 3 | 25 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for metformin and Hepatitis C, Chronic
| Article | Year |
|---|---|
Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Hepatitis C, Chronic; Humans; Hypoglycemic Age | 2013 |
Insulin resistance and response to antiviral therapy in chronic hepatitis C: mechanisms and management.
Topics: Animals; Antiviral Agents; Diabetes Mellitus, Type 2; Fatty Liver; Glucose Clamp Technique; Hepatiti | 2010 |
[Improved virologic response in chronic hepatitis C treated with peginterferon, ribavirin and add-on drug].
Topics: Antiviral Agents; Cyclosporine; Diterpenes; Drug Therapy, Combination; Fatty Acids, Monounsaturated; | 2011 |
4 trials available for metformin and Hepatitis C, Chronic
| Article | Year |
|---|---|
Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers.
Topics: Administration, Oral; Adult; Area Under Curve; Blood Glucose; Carbamates; Cross-Over Studies; Diabet | 2017 |
A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin.
Topics: Acarbose; Adult; Aged; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination | 2014 |
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin.
Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepatitis | 2009 |
The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance.
Topics: Adult; Antibodies, Viral; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Enzyme-Lin | 2012 |
13 other studies available for metformin and Hepatitis C, Chronic
| Article | Year |
|---|---|
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Diabetes Mellitus; Hepatitis C, C | 2023 |
Additional Inhibition of Wnt/β-Catenin Signaling by Metformin in DAA Treatments as a Novel Therapeutic Strategy for HCV-Infected Patients.
Topics: Antiviral Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colony-Forming Units Assay; G1 Ph | 2021 |
Comparison of metformin and pioglitazone in achieving sustained virological response in chronic hepatitis C patients with insulin resistance: A quasi-experimental study.
Topics: Adult; Antiviral Agents; Blood Glucose; Female; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; I | 2017 |
Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy.
Topics: Autophagy; Biomarkers, Tumor; Carcinoma, Hepatocellular; Caspase 3; Cell Line; Cell Proliferation; C | 2018 |
Hyperinsulinemia and risk for hepatocellular carcinoma in patients with chronic liver diseases and Type 2 diabetes mellitus.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Hepatitis C, Chronic; Humans; Hyperins | 2009 |
Metformin in chronic hepatitis C virus hepatitis: caution needed with sex-based subgroup analysis.
Topics: Female; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Sex | 2010 |
Metformin, hepatitis C, and insulin resistance: sufficient evidence?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Int | 2009 |
Metformin improves sustained virologic response in difficult-to-cure hepatitis C: more questions than answers.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Metformin; Ribavirin | 2010 |
Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C.
Topics: Antiviral Agents; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyc | 2011 |
Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients.
Topics: Aged; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Hepatitis C, | 2011 |
Impact of insulin-sensitizing agents on risk for liver cancer and liver-related death in diabetic patients with compensated hepatitis C cirrhosis.
Topics: Diabetes Mellitus, Type 2; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Metformin | 2011 |
Protein-tyrosine phosphatases are involved in interferon resistance associated with insulin resistance in HepG2 cells and obese mice.
Topics: Animals; Antiviral Agents; Enzyme Inhibitors; Gene Knockdown Techniques; Gene Silencing; Hep G2 Cell | 2012 |
Artificially low HbA1c associated with treatment with ribavirin.
Topics: Antiviral Agents; Diabetes Mellitus; Glycated Hemoglobin; Hepatitis C, Chronic; Humans; Hypoglycemic | 2008 |